New hope for advanced lung cancer patients out of options
NCT ID NCT06761976
Summary
This program provides access to an investigational oral drug called sevabertinib for adults with advanced non-small cell lung cancer that has a specific genetic mutation (HER2). It's designed for people whose cancer has progressed after at least one prior treatment and who have no other therapeutic options available. The goal is to control the cancer's growth and progression.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.